BioSpace News Archive

Under the deal, Merus has agreed to lead research and discovery activities while Simcere has agreed to be responsible for the Investigational New Drug (IND) enabling studies, clinical development, regulatory filings and commercialization of these product candidates in China.

ASLAN Pharma today announced that commercialisation of varlitinib in China.

The trial’s primary endpoint, the reduction in the patient-reported visual analog scale (VAS) for pain at Week 8, showed a robust impact on pain, with a greater than 50% reduction for patients treated with RT002.

Under the agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms (MPNs), and Incyte will receive options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets

The agreement validates Teva’s IP and resolves Alder’s opposition to Teva’s European Patent No. 1957106 B1.

The Company expects fourth quarter 2017 revenue to be approximately $272M and full year 2017 revenue to be approximately $1,030M and in line with the guidance provided on Oct 24, 2017.

Cerus’ unaudited preliminary product revenue for the fourth quarter of 2017 was $16.2 million, an increase of 60% compared to fourth quarter of 2016.

This unique offering follows the acquisition of Chiltern, a leading contract research organization with a track record of engagement models that meet the specific needs of these client segments.

Olainfarm” invites shareholders, investors, mass media representatives and other stakeholders to join its investor conference webinar scheduled on January 11, 2018 at 16:00 (EET).

The name change reflects the Company’s plan to exclusively focus on the late-stage clinical research and commercialization of gene-based biotherapeutics for niche markets in the oncology and cardiology spaces for patients with unmet medical needs.